Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes

Lancet

Volumn 351, Issue 9095, 1998, Pages 28-31

  Chaturvedi, Nish ^a   Sjolie, Anne Katrin ^b   Stephenson, Judith M ^a   Abrahamian, Heidemarie ^c   Keipes, Marc ^f   Castellarin, Allesandro ^d   Rogulja Pepeonik, Zeljka ^e   Fuller, John H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c City of Vienna Hospital Lainz   (Austria)

^d UNIVERSITY OF VERONA   (Italy)

^e Merkur University Hospital   (Croatia)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLUCOSE; LISINOPRIL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PHOTOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032477583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06209-0     Document Type: Article

References (27)

1. 1 Dwyer MS, Melton III LJ, Ballard DJ, Palumbi PJ, Trautman JC, Chu CP. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 1985; 8: 316-22.
2. 2 Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologie Study of diabetic retinopathy II prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-60.
3. 3 Sjolie AK, Stephenson J, Aldington S, et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. Ophthalmology 1997; 104: 252-60.
4. 4 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. 5 Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427-32.
6. 6 Janka HU, Warram JH, Rand LI, Krolewski AS. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 1989; 38: 460-64.
7. 7 Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246-51.
8. 8 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, and the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
9. 9 The Microalbumin Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-93.
10. 10 Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284-89.
11. 11 Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-09.
12. 12 The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
13. 13 The EURODIAB IDDM Complications Study Group. Microvascular and acute complications in insulin dependent diabetes mellitus. Diabetologia 1994; 37: 278-85.
14. 14 Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie A-K, The EURODIAB IDDM Complications Study Group. Methodolgy for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 437-44.
15. 1c. Clin Chem 1993; 39: 663-66.
16. 16 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
17. 17 Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81.
18. 18 Woolf B. On estimating the relation between blood group and disease. Am Hum Genet 1995; 19: 251-53.
19. 19 Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol 1992; 24: 99-103.
20. 20 The DCCT Research Group. The Diabetes Control and Complications Trials (DCCT): design and methodologic consideration for the feasibility phase. Diabetes 1986; 35: 530-44.
21. 21 Feman SS, Mericle RA, Reed GW, May JM, Workman RJ. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993; 305: 280-84.
22. 22 Parving HH, Larsen M, Hommel E, Lund Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy. Diabetologia 1989; 32: 440-44.
23. 23 Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
24. 24 Caldwell PRB, Seegal BC, Hsu KC, Das M, Soffer R. Angiotensin converting enzyme, vascular endothelial localization. Science 1976; 191: 1050-51.
25. 25 Engler CB, Parving H-H, Mathiesen ER, Larsen M, Lund-Andersen H. Blood-retina barrier permeability in diabetes during ACE inhibition. Acta Ophthalmol 1991; 69: 581-85.
26. 26 Herman WH, Dasbach EJ, Songer TJ, Thompson DE, Crofford OB. Assessing the impact of intensive insulin therapy on the health care system. Diabetes Rev 1994; 2: 384-88.
27. 27 The DCCT Research Group. Epidemiology of severe hypoglycaemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450-59.